- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04966858
Individuel undersøgelse af genfodring for at optimere indlæggelsesgevinster (i-STRONG)
Fornyelse af Multicenter Randomized Controlled Trial of Refeeding in Anorexia Nervosa
The primary purpose of the trial is to compare the efficacy and safety of Individualized Caloric Refeeding (ICR) to the new standard of care, Higher Calorie Refeeding (HCR), in hospitalized patients with atypical anorexia nervosa (AAN), and clinical remission over one year of follow-up.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Atypical Anorexia Nervosa (AAN) is a new diagnosis describing patients with malnutrition and significant weight loss yet "normal" weight. These patients responded poorly to HCR, the superior refeeding treatment in the parent trial, which was designed for low-weight patients with typical AN. The proposed trial will examine the safety and efficacy of a new treatment for AAN with the potential to improve treatment outcomes for this diverse and growing patient population. The major finding motivating the proposed trial is that participants with AAN gained weight 40 percent slower and required 3.0 additional days in hospital to restore medical stability on HCR, as compared to AN. The research team has developed Individualized Caloric Refeeding (ICR), which doses calories to weight consistent with other pediatric treatments (e.g. medication).
The primary purpose of the proposed trial is to compare the efficacy and safety of ICR to the new standard of care (HCR) in hospitalized patients with AAN. The investigators hypothesize that ICR will restore medical stability faster than HCR with no increase in electrolyte abnormalities. After hospitalization, the major barrier to care in AAN is lack of consensus on clinical remission and whether these formerly overweight patients should gain weight to recover. The research team will examine metabolic, hormonal and psychological markers during long-term follow-up, toward the goal of developing a definition of clinical remission in AAN.
Design Summary: Randomized controlled trial in N=74 participants age 12-24 with AAN, consented upon hospital admission, randomly assigned to ICR or HCR, followed daily in hospital and at 3, 6, 9 and 12 mo.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
California
-
Palo Alto, California, Forenede Stater, 94304
- Stanford University Lucille Packard Children's Hospital
-
San Francisco, California, Forenede Stater, 94158
- University of California, San Francisco Benioff Children's Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Age 12-24 yrs
-
Meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for AAN
-
Hospitalized with medical instability, as defined by:
- night time heart rate (HR) <45 bpm,
- systolic blood pressure (SBP) <90 mmHg,
- temperature <35.6° C,
- orthostatic Δ HR >35 bpm, or
- orthostatic Δ SBP >20 mmHg
Exclusion Criteria:
- Bulimia nervosa
- Current pregnancy
- Chronic disease (e.g. immune, renal disease)
- Acute/active suicidality or psychosis
- Hospital admissions for refeeding in the prior 6 mo.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Individualized Caloric Refeeding (ICR)
Starting 50 kcal/kg/d, increasing by 200 kcal/d to goal |
Meal-based refeeding in hospital, starting at 50 calories per kilogram of body weight, and increasing by 200 calories per day until caloric goal achieved
Andre navne:
|
|
Aktiv komparator: Higher Calorie Refeeding (HCR)
Starting 2000 kcal/d, increasing by 200 kcal/d to goal |
Meal-based refeeding in hospital, starting at 2000 calories per day, and increasing by 200 calories per day until caloric goal achieved
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to Achieve Medical Stability in Hospital
Tidsramme: Inpatient hospitalization from day of admission to day of discharge, average 1-2 weeks
|
Medical stability will be adjudicated by a five-point index: (1) 24 hour heart rate of 45 beats/min or more, (2) systolic blood pressure of 90 millimeters of mercury (mmHg) or more, (3) temperature of 35.6° C or more, (4) orthostatic increase in heart rate of 35 beats/min or less, (5) orthostatic change in systolic blood pressure of 20 mmHg or less. |
Inpatient hospitalization from day of admission to day of discharge, average 1-2 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Low Serum Electrolytes During Refeeding in Hospital
Tidsramme: Inpatient hospitalization from day of admission to day of discharge, average 1-2 weeks
|
Incidence of low electrolytes will be defined as: (1) hypophosphatemia less than 3 milligrams per deciliter (mg/dL), (2) hypomagnesaemia less than 1.8 mg/dL, and (3) hypokalemia less than 3.5 milliequivalent per liter (mEq/L) during hospitalization. |
Inpatient hospitalization from day of admission to day of discharge, average 1-2 weeks
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage Median BMI (mBMI) Over 12 Months
Tidsramme: 12 months post-study hospitalization
|
Measured BMI will be divided by the mBMI for age and sex per national growth data to give the percentage mBMI. |
12 months post-study hospitalization
|
|
Eating Disorder Examination Questionnaire (EDE-Q) Score Over 12 Months
Tidsramme: 12 months post-study hospitalization
|
The EDE-Q will be self-administered; scores range from 0 to 6, with higher scores indicating greater severity and a worse outcome. |
12 months post-study hospitalization
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Andrea K Garber, PhD, RD, University of California, San Francisco
- Ledende efterforsker: Neville H Golden, MD, Stanford University
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2R01HD082166-06A1 (U.S. NIH-bevilling/kontrakt)
- 20-32551 (Anden identifikator: UCSF IRB)
- R01HD082166 (U.S. NIH-bevilling/kontrakt)
- HD082166 (Anden identifikator: Federal Identifier, per NIH application)
- P0547076 (Anden identifikator: NIH Application Identifier)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .